Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Weill Cornell Medicine has secured a grant of approximately $4m for a trial to assess a new imaging approach in prostate ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

Weill Cornell Medicine celebrated the opening of the Feil Family and Weill Family Residence Hall with a ribbon-cutting ...

One study, presented here at the annual meeting of the Society for Investigative Dermatology (SID), reported a 965% increase ...

Doha – Weill Cornell Medicine-Qatar (WCM-Q) has become the first medical institution in Qatar to receive official designation ...